Niedermolekulare Heparine Eine Übersicht über Wirkprofil und bisherige klinische Anwendung

• Literatur

• 1 Abildgaard U. Purification of two progressive antithrombins of human plasma. Scand J clin Lab Invest 1967; 19: 190-5.
• 2 Aillaud M F, Elias A, Alessi M C, Lecorf G, Bouvier J L, Roul C, Serradimigni A, Juhan-Vague I. Treatment of deep vein thrombosis (DVT) with LMWH CY 222. Thrombolysis and plasma fibrinolytic parameters. Fibrinolysis. Abstr. 179, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 3 Andersson L O, Barrowcliffe T W, Holmer E, Johnson E A, Sims G E C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 09: 575-83.
• 4 Andersson L O, Barrowcliffe T W, Holmer E, Johnson E A, Söderström G. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma. Thromb Res 1979; 15: 531-41.
• 5 Bagge L, Nyström S O, Tydén H, Holmer E, Malm T, Wahlberg T. Coagulation and fibrinolysis when using fragmin during cardiopulmonary by-pass (CPB) in vitro and in vivo. Fibrinolysis. Abstr. 181, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 6 Barbanti M, Mastacchi R, Bianchini P. Systemic fibrinolytic activity of sulfated polysaccharides. Fibrinolysis. Abstr. 331, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 7 Barrowcliffe T W, Johnson E A, Eggleton C A, Kemball-Cook G, Thomas D P. Anticoagulant activities of high and low molecular weight heparin fractions. Br J Haematol 1979; 41: 573-83.
• 8 Barrowcliffe T W, Merton R E, Havercroft S J, Thunberg L, Lindahl U, Thomas D P. Low affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb Haemost 1983; 50: 183 (Abstr).
• 9 Bengtsson G, Olivecrona T. Interaction of lipoprotein lipase with heparin-sepharose. Evaluation of conditions for affinity binding. Biochem J 1977; 167: 109-19.
• 10 Bengtsson G, Olivecrona T, Höök M, Lindahl U. Interaction of heparin with proteins. Demonstration of different binding sites for antithrombin and lipoprotein lipase. FEBS Lett 1977; 79: 59-63.
• 11 Bengtsson G, Olivecrona T, Höök M, Riesenfeld J, Lindahl U. Interaction of lipoprotein lipase with native and modified heparin-like polysaccharides. Biochem J 1980; 189: 625-33.
• 12 Bergqvist D, Burmark U S, Frisell J, Hallböök T, Lindblad B, Risberg B, Törngren S, Wallin G. Prospective doubleblind comparison between fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986; 16 (Suppl. 02) 11-8.
• 13 Binsack T, Zellner M, Schimming I, Wirth C, Moser E, Riess H, Hiller E. Thrombosis prophylaxis with LMW heparin and sodium heparin in patients with total hip replacement. Thromb Res 1986; Suppl VI: 83 (Abstr).
• 14 Boneu B, Bemecheckroun S, Goudable C, Sié P. Heparin pharmacokinetics in deep vein thrombosis. Thromb Res 1986; Suppl VI: 89 (Abstr).
• 15 Borm J J J, Krediet R, Sturk A, ten Cate J W. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 1986; 16 (Suppl. 02) 59-68.
• 16 Bratt G, Törnebohm E, Granqvist S, Åberg W, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 1985; 54: 813-7.
• 17 Breyer H G, Al-Therib J, Bacher P, Werner B. Thrombosis prophylaxis with low molecular weight heparin in trauma surgery. Thromb Res 1986; Suppl VI: 84 (Abstr).
• 18 Carter C J, Kelton J G, Hirsh J, Gent M. Relationship between the antithrombotic and anticoagulant effects of low molecular weight heparin. Thromb Res 1981; 21: 169-74.
• 19 Carter C J, Kelton J G, Hirsh J, Cerskus A, Santos A V, Gent M. The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-45.
• 20 Choay J, Lormeau J C, Petitou M, Sinay P, Casu B, Oreste P, Torri G, Gatti G. AntiXa active heparin oligosaccharides. Thromb Res 1980; 18: 573-8.
• 21 Choay J, Lormeau J C, Petitou M, Torri G, Sinay P. Physico-chemical studies on oligosaccharides from porcine mucosal heparin. Thromb Haemost 1981; 46: 236 (Abstr).
• 22 Choay J, Lormeau J C, Petitou M. Physical, chemical, biological characteristics and sequence of the antithrombin III binding site of the heparin low molecular weight fraction CY 216. Haemostasis 1982; 12: 219 (Abstr).
• 23 Choay J, Fareed J, Andersen A, Stulc J, Ward M. Studies on the antithrombotic action of a low molecular weight heparin fraction in a stasis thrombosis rabbit model. Fed Proc 1982; 41: 919 (Abstr).
• 24 Danishefsky I, Radoff S. Location of the anticoagulant-conferring area on the heparin chain. Thromb Haemost 1983; 50: 102 (Abstr).
• 25 Doutremepuich C, Gestreau J L, Maury M O, Quilichini R, Boisseau M R, Toulemonde F, Vairel E. Experimental venous thrombosis in rats treated with heparin and a low molecular weight heparin fraction. Haemostasis 1983; 13: 109-12.
• 26 Dunn F, Soria J, Soria C, Thomaidis A, Tobelem G, Caen J P. Fibrinogen binding on human platelets. Influence of different heparins and of pentosane polysulfate. Thromb Res 1983; 29: 141-8.
• 27 Einarsson R, Andersson L O. Binding of heparin to human antithrombin III as studied by measurements of tryptophan fluorescence. Biochem Biophys Acta 1977; 490: 104-11.
• 28 Eriksson E, Wollter I M, Christenson B, Stigendal L, Risberg B. Enhancement of fibrinolysis by heparin. Fibrinolysis Abstr. 329, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 29 Esquivel C O, Bergqvist D, Björck C G, Nilsson B. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulfate on hemostasis and platelets in vivo. Thromb Res 1982; 28: 389-99.
• 30 Faivre R, Fareed J, Neuhart E, Kieffer Y, Petiteau P Y, Toulemonde F, Bassand J P, Maurat J P. Effects on clotting and fibrinolytic system of a low molecular weight heparin (CY 222) in patients with deep venous thrombosis. Preliminary result of a randomized trial. Fibrinolysis Abstr. 352, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 31 Fareed J, Kumar A, Walenga J M, Emanuele R M, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fractions and fragments. Nouv Rev Fr Hematol 1984; 26: 267-75.
• 32 Fareed J, Walenga J M, Williamsen K, Emanuele R M, Kumar A, Hoppensteadt D. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments. Sem Thromb Hemost 1985; 11: 56-74.
• 33 Fareed J. Heparin, its fractions, fragments and derivatives. Some newer perspectives. Sem Thromb Hemost 1985; 11: 1-9.
• 34 Fareed J, Walenga J M, Hoppensteadt D A, Messmore H L. Studies on the profibrinolytic actions of heparin and its fractions. Sem Thromb Hemost 1985; 11: 199-207.
• 35 Gensini G F, Fortini A, Lombardi A, Pesciullesi E, Pieroni C, Neri Serneri G. Binding of low-molecular-weight heparin to aortic endothelium in rabbits. Haemostasis 1984; 14: 466-72.
• 36 Haas S, Stemberger A, Wendt P, Vinazzer H, Blümel G. The effects of low molecular weight heparin on various parameters of blood coagulation and fibrinolysis. Thromb Haemost 1983; 50: 224 (Abstr).
• 37 Haas S, Fritsche H M, Hasner F, Stemberger A, Wendt P, Wolf H. Study of the anticoagulant and antithrombotic effect of low molecular weight heparin DHE (LMWH-DHE) in total hip replacement under double-blind conditions. Thromb Haemost 1985; 54: 92 (Abstr).
• 38 Haas S, Stemberger A, Wendt P, Zeisel H J, Blümel G. Does low molecular weight heparin accumulate after repeated application?. Thromb Haemost 1985; 54: 34 (Abstr).
• 39 Haas S, Fritsche H M, Stemberger A, Blümel G, Lechner F. Antithrombotische Wirksamkeit und Verträglichkeit des niedermolekularen Heparins Sandoz bei elektivem Hüftgelenkersatz. Acta Chir Austriaca 1986; 03: 380-1.
• 40 Haas S, Fritsche H M, Stemberger A, Blümel G, Lechner F. Einfluß des niedermolekularen Heparins Fragmin® (KABI) auf die Blutgerinnung und postoperative Thrombose. Acta Chir Austriaca 1986; 03: 381-2.
• 41 Harenberg J, de Vries J X. Characterization of heparins by high-performance size exclusion liquid chromatography. J Chromatogr 1983; 261: 287-92.
• 42 Harenberg J, Fussi F, Augustin J, Haberbosch W, Zimmermann R. Haemostatic and lipolytic effects of unfractionated and low molecular weight heparin. Thromb Haemost 1983; 50: 73.
• 43 Holm H A, Ly B, Handeland G F, Abildgaard U, Arnesen K E, Gottschalk P, Hoeg V, Aandahl M, Haugen K, Laerum F, Scheel B, Sortland O, Vinje B. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 1986; 16 (Suppl. 02) 30-7.
• 44 Holmer E. Anticoagulant properties of heparin and heparin fractions. J Haematol 1980; 25 (Suppl. 036) 25-39.
• 45 Holmer E, Lindahl U, Bäckström G, Thunberg L, Sandberg H, Söderström G, Andersson L O. Anticoagulant activities and effects on platelets of a heparin fragment with high affinity for antithrombin. Thromb Res 1980; 18: 861-9.
• 46 Holmer E, Kurachi K, Söderström G. The molecular weight dependence of the rateenhancing effect of heparin on the inhibition of thrombin, Factor Xa, Factor IXa, Factor XIa, Factor Xlla and kallikrein by antithrombin. Biochem J 1981; 193: 395-400.
• 47 Holmer E, Mattsson C, Nilsson S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 1982; 25: 475-86.
• 48 Holmer E, Bergqvist D, Hedner U. Anticoagulant effects in human volunteers after subcutaneous administration of heparin and of two types of low molecular weight heparin. Thromb Haemost 1983; 50: 91 (Abstr).
• 49 Holmer E, Söderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis 1986; 16 (Suppl. 02) 1-7.
• 50 Hoylaerts M, Holmer E, de Mol M, Collen D. Covalent complexes between low molecular weight heparin fragments and antithrombin III Inhibition kinetics and turnover parameters. Thromb Haemost 1983; 49: 109-15.
• 51 Huisse M G, Guillin M C, Bezeaud A, Toulemonde F, Kitzis M, Andreassian B. Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thromb Res 1982; 27: 485-90.
• 52 Johnson E A, Kirkwood T B L, Stirling Y, Perez-Requejo J L, Ingram G I C, Bangham D R, Brozovic M. Four heparin preparations: anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemost 1976; 35: 586-91.
• 53 Jordan R, Beeler D, Rosenberg R. Fractionation of low molecular weight heparin species and their interaction with antithrombin. J Biol Chem 1979; 254: 2902-13.
• 54 Kakkar V V. The current status of lowdose heparin in the prophylaxis of thrombophlebitis and pulmonary embolism. World J Surg 1978; 02: 3-18.
• 55 Kakkar V V, Bentley P G, Lawrence D, de Haas H A, Ward V P. Die Prophylaxe der postoperativen venösen Thromboembolie beim Hüftgelenksersatz mit Heparin und Dihydroergotamin. Münch Med Wschr 1979; 36: 1152-4.
• 56 Kakkar V V, Djazaeri B, Fok J, Fletcher M, Scully M F, Westwick J. Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis. Br Med J 1982; 284: 375-9.
• 57 Kakkar V V. Prevention of post-operative venous thromboembolism by a new molecular weight heparin fraction. Nouv Rev Fr Hematol 1984; 26: 277-82.
• 58 Kakkar V V, Murray W J G. Efficacy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thrombo-embolism : a co-operative study. Br J Surg 1985; 72: 786-91.
• 59 Kakkar V V, Kakkar S, Sanderson R M, Peers C E. Efficacy and safety of two regimens of low molecular weight heparin fragment (fragmin) in preventing postoperative venous thromboembolism. Haemostasis 1986; 16 (Suppl. 02) 19-24.
• 60 Koller M, Schoch U, Buchmann P, Largiadèr F, von Felten A, Frick P G. Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/ day). Haemostasis 1986; 16 (Suppl. 02) 69-70.
• 61 Lam L H, Silbert J E, Rosenberg R D. The separation of active and inactive forms of heparin. Biochem Biophys Res Commun 1976; 69: 570-7.
• 62 Lane D A, Flynn A, Ireland H, Anastassiades E, Curtis J R. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure. Haemostasis 1986; 16 (Suppl. 02) 38-47.
• 63 Laurent T C. Studies on fractionated heparin. Arch Biochem Biophys 1961; 92: 224-31.
• 64 Laurent T C, Killander J. A theory of gel filtration and its experimental verification. J Chromatogr 1964; 14: 317-30.
• 65 Linhardt R J, Grant A, Cooney C L, Langer R. Differential anticoagulant activity of heparin fragments prepared using microbial heparinase. J Biol Chem 1982; 257: 7310-3.
• 66 MacGregor I R, Lane D A, Kakkar V V. The anti-heparin properties of human lowdensity lipoprotein. Biochem Biophys Acta 1980; 617: 472-9.
• 67 Mardiguian J, Trillou M. Studies on heparin octadecasaccharide fragments. Thromb Haemost 1983; 50: 223 (Abstr).
• 68 Maroske D. Wirkungsprüfung von niedermolekularem Heparin in fixer Kombination mit Dihydroergotamin und HeparinDHE® in der Traumatologie. Gutachten für B G A/Zulassungsdossier; 1985
• 69 Mattsson C, Hoylaerts M, Holmer E, Uthne T, Collen D. Antithrombotic properties in rabbits of heparin and heparin fragments covalently coupled to human antithrombin III. J Clin Invest 1985; 75: 1169-73.
• 70 Merton R E, Thomas D P, Havercroft S J, Barrowcliffe T W, Lindahl U. High and low affinity heparin compared with unfractionated heparin as antithrombotic drugs. Thromb Haemost 1984; 51: 254-6.
• 71 Neerstrand H, Hedner U, Ostergaard P, Bergqvist D, Mätzsch T. t-PA inhibitor, tPA: AG, and plasminogen after low molecular weight heparin or standard heparin. Fibrinolysis. Abstr. 178, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 72 Ockelford P A, Carter C J, Cerskus A, Smith C A, Hirsh J. Comparison of the in vivo hemorrhagic and antithrombotic effects of a low antithrombin-III affinity heparin fraction. Thromb Res 1982; 27: 679-90.
• 73 Ockelford P A, Charter C J, Mitchell L, Hirsh J. Discordance between the anti-Xa activity and the antithrombotic activity of an ultra-low molecular weight heparin fraction. Thromb Res 1983; 28: 401-9.
• 74 Oosta G M, Gardner W T, Beeler D L, Rosenberg R D. Multiple functional domains of the heparin molecule. Proc Natl Acad Sci 1981; 75: 829-33.
• 75 Racanelli A, Fareed J, Walenga J M, Coyne E. Biochemical and pharmacologic studies on the protamine interactions with heparin, its fractions and fragments. Sem Thromb Hemost 1985; 11: 176-89.
• 76 Rosenberg R D. Actions and interactions of antithrombin and heparin. New Engl J Med 1975; 292: 146-51.
• 77 Rosenberg R D, Armand G, Lam L. Structure-function relationships of heparin species. Proc Natl Acad Sei USA 1978; 75: 3065-9.
• 78 Rosenberg R D, Jordan R E, Favreau L V, Lam L H. Highly active heparin species with multiple binding sites for antithrombin. Biochem Biophys Res Commun 1979; 86: 1319-24.
• 79 Rosenberg R D, Lam L. Correlation between structure and function of heparin. Proc Natl Acad Sei USA 1979; 76: 1218-22.
• 80 Roussi J, Houbouyan L, Rosenthal D, Toulemonde F, Goguel A. Succès du traitement par une fraction d’héparine de bas poids moléculaire dans un cas d’embolie pulmonaire compliquant une thrombopénie induite par l’héparine. Nouv Rev Fr Hématol 1983; 25: 273-4.
• 81 Roussi J H, Houbouyan L L, Goguel A F. Use of low-molecular-weight heparin in heparin-induced thrombocytopenia with thrombotic complications. Lancet 1984; I 8387 1183.
• 82 Rutilant M L, Fontcuberta J, MartmezJubitero J M, Borrell M. The influence of low molecular weight heparin (LMWH) or standard heparin (UFH) on fibrinolysis. Fibrinolysis. Abstr. 205, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 83 Rutilant M L, Fontcuberta J, MartmezJubitero J M, Cairols M, Rosendo A. Treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH, CY-216 Choay) compared to standard heparin (UFH). Fibrinolysis. Abstr. 346, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 84 Rutilant M L, Fontcuberta J, MartmezJubitero J M, Cairols M, Rosendo A. Subcutaneous low molecular weight heparin (LMWH Kabi-2165) or unfractionated heparin (UFH) in the treatment of deep venous thrombosis (DVT). Fibrinolysis. Abstr. 350, 8th Internat. Congress on Fibrinolysis: Vienna; 1986
• 85 Salzman E W, Rosenberg R D, Smith M H, Lindon J N, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64-73.
• 86 Sasahara A A, Koppenhagen K, Färing R, Welzel D, Wolf H. Low molecular weight heparin + dihydroergotamine for prophylaxis of post operative deep vein thrombosis. Br J Surg 1986; 73: 697-700.
• 87 Silane M, Lindon J N, Ransil B J, Rosenberg R D, Salzman E W. Platelet aggregation induced in vivo by heparin and heparin fractions. Thromb Haemost 1981; 46: 194 (Abstr).
• 88 de Swart C A M, Sixma J J, Nijmeijer A, Holmer E, Andersson L O, Verschoor L. Kinetics of anticoagulant and lipolytic activity and radiolabel after intravenous administration of 35 S-heparin fractions of different molecular weight. Thromb Haemost 1981; 46: 185 (Abstr).
• 89 Schmitz-Hübner U, Balleisen L, Asbeck F, van de Loo J. In vivo studies on the inhibition of coagulation by fractionated heparin and by a heparin analogue. - I. Effects of heparin fractions. Thromb Haemost 1981; 46: 612-6.
• 90 Schmitz-Hübner U. Gerinnungsphysiologische Wirkungen niedrigdosierten Heparins, fraktionierten Heparins und verwandter Mucopolysaccharide. Habilitationsschr. Münster; 1982
• 91 Schrader J, Kandt M, Zürcher C, Köstering H, Scheler F. Comparison of unfractionated heparin and low molecular weight heparin during long-term use in chronic haemodialysis and haemofiltration patients. Haemostasis 1986; 16 (Suppl. 02) 48-58.
• 92 Stone A L, Beeler D, Oosra G, Rosenberg R D. Circular dichroism spectroscopy of heparin-antithrombin interactions. Proc Natl Acad Sei USA 1982; 79: 7190-4.
• 93 Thomas D P, Merton R E, Lewis W E, Barrowcliffe T W. Studies on man and experimental animals of a low molecular weight heparin fraction. Thromb Haemost 1981; 45: 214-8.
• 94 Thomas D P, Merton R E, Barrowcliffe T W, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-8.
• 95 Thomson C, Forbes C D, Prentice C R M. The potentiation of platelet aggregation and adhesion by heparin in vitro and in vivo. Clin Sci Mol Med 1973; 45: 485-94.
• 96 Tscherne H, Westermann K, Trentz O, Pretschnow P, Mellmann J. Thromboembolische Komplikationen und ihre Prophylaxe beim Hüftgelenkersatz. Unfallheilkunde 1978; 81: 178-87.
• 97 Vairel E G, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsh N A, Gaffney P J. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
• 98 Vergnes C, Janvier G, Winnock S, Lorient M FRoudaut, Freyburger G, Crocket J, Bosseau M R. Treatment of deep venous thrombosis with CY 222: biologic data. Fibrinolysis. Abstr 182. 8th Internat Congress on Fibrinolysis: Vienna; 1986
• 99 Vinazzer H, Stemberger A, Haas S. Effect of heparin fractions and of low molecular weight heparin-like substances on fibrinolysis. Haemostasis 1982; 12: 123.
• 100 Vinazzer H, Stemberger A, Haas S, Blümel G. Influence of heparin, of different heparin fractions and of low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-52.
• 101 Wessler S, Reimer S M, Sheps M C. Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-6.
• 102 Yin E T. Effect of heparin on the neutralization of factor Xa and thrombin by the plasma alpha-II globulin inhibitor. Thromb Diathes Haemorrh 1975; 33: 43-50.
• 103 Zimmermann R, Harenberg J. Gutachten für BGA/Zulassungsdossier. 1985